Promoting remyelination in multiple sclerosis: Current drugs and future prospects

Multiple Sclerosis Journal - Tập 21 Số 5 - Trang 541-549 - 2015
David Kremer1, Patrick Küry2, Ranjan Dutta3
1Department of Neurology, Medical Faculty, University of Düsseldorf, Germany/Department of Neurosciences, Lerner Research Institute, USA
2Department of Neurology, Medical Faculty, University of Düsseldorf, Germany
3Department of Neurosciences, Lerner Research Institute, USA

Tóm tắt

Myelin destruction due to inflammatory oligodendrocyte cell damage or death in conjunction with axonal degeneration are among the major histopathological hallmarks of multiple sclerosis (MS). The majority of available immunomodulatory medications for MS are approved for relapsing–remitting (RR) MS, for which they reduce relapse rate, MRI measures of inflammation, and the accumulation of disability. These medications are, however, of little benefit during progressive MS where axonal degeneration following demyelination outweighs inflammation. This has sparked great interest in the development of new remyelination therapies aimed at reversing the neurodegenerative damage observed in this disease. Remyelination as a result of oligodendrocyte production from oligodendrocyte precursor cells (OPCs) is considered a promising potential target for the treatment of all stages of MS. In this review we present an overview of a) approved medications (some of them FDA-and EMA-approved for other diseases) with a proposed role in regeneration, b) regenerative treatments under investigation in clinical trials, and c) promising future therapeutic approaches aiming specifically at facilitating endogenous repair.

Từ khóa


Tài liệu tham khảo

Charcot JM, 1868, Gaz Hosp, 41, 554

10.1016/S1474-4422(14)70068-7

Cocco E, 2014, Mult Scler

10.1177/1352458513502572

10.1146/annurev.neuro.30.051606.094313

10.1016/S1474-4422(09)70043-2

10.1007/s11910-007-0036-0

10.1038/nrneurol.2012.168

10.1038/nrneurol.2012.200

10.1523/JNEUROSCI.20-17-06404.2000

10.1056/NEJMoa010994

10.1002/ana.23693

10.1002/ana.410050105

10.1002/ana.22415

10.1016/j.ccr.2014.02.018

10.1038/nm781

10.1016/S0896-6273(00)80515-2

10.1016/S0092-8674(03)00810-9

10.1038/nature02284

10.1016/j.jns.2008.06.031

10.1002/glia.20576

10.2353/ajpath.2010.091234

10.1073/pnas.1014154108

10.1007/s00401-012-1014-4

10.1038/nature12647

10.1038/nn1460

10.1007/s40263-013-0068-8

10.1002/jnr.21217

10.1586/14737175.2013.835601

10.1038/nrg3199

10.1007/s12016-009-8170-x

10.1111/j.1600-0404.1997.tb08148.x

10.1002/ana.23970

Kremer D, 2014, Mult Scler

Derfuss T, 2014, Neurology, 82, P2.217, 10.1212/WNL.82.10_supplement.P2.217

10.1111/j.1471-4159.2012.07883.x

10.1038/sj.mp.4002064

10.1016/j.schres.2012.04.006

10.1093/brain/awq386

Wang RR, 2014, Mult Scler, 20, 285, 10.1177/1352458514547846

10.4049/jimmunol.1203137

10.1038/nm.3618

10.1016/j.mcn.2011.12.004

10.4049/jimmunol.172.2.1246

10.4161/tisb.23272

Jonason A, 2014, Mult Scler, 20, 285, 10.1177/1352458514547846

10.1038/nn.2702

Sanders M, 2014, Neurology, 82, S14.006, 10.1212/WNL.82.10_supplement.S14.006

10.1200/jco.2014.32.4_suppl.169

10.1124/jpet.107.123000

10.1111/ene.12344

10.1002/ana.22593

10.1016/j.jneuroim.2005.10.013

10.1016/j.expneurol.2009.12.020

10.1146/annurev-neuro-061010-113629

10.1038/nn1374

10.1242/dev.02590

10.4161/epi.4.5.9371

Thông tin
Thông tin xuất bản

Multiple Sclerosis Journal

Tập 21 Số 5

541-549

Thông tin tác giả